Back to Search
Start Over
A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using multicatheter interstitial brachytherapy: clinical results with a median follow-up of 60 months.
- Source :
-
Breast cancer (Tokyo, Japan) [Breast Cancer] 2022 Jul; Vol. 29 (4), pp. 636-644. Date of Electronic Publication: 2022 Mar 18. - Publication Year :
- 2022
-
Abstract
- Background: We carried out the first multi-institutional prospective study on accelerated partial breast irradiation (APBI) via multicatheter interstitial brachytherapy in a shorter period for early breast cancer in Japan.<br />Methods: Patient eligibility criteria included positive hormone receptors, tumors ≤ 3 cm and TNM stage pN0M0. After breast-conserving surgery (Japanese cylindrical resection) and histological confirmation of negative surgical margins and the absence of lymph node metastasis, applicator implantation was performed either postoperatively or intraoperatively. High-dose-rate brachytherapy of 36 Gy in 6 fractions was delivered.<br />Results: Forty-six patients from six institutions received this treatment regimen, and the median follow-up time was 60 months (range 57-67 months). The median resected breast tissue volume was 81 cm <superscript>3</superscript> (range 28-260 cm <superscript>3</superscript> ). No Grade 4 late sequela, local recurrence nor death due to breast cancer were observed. Grade 2-3 sequelae such as rib fracture (2%), soft tissue necrosis (9%), fibrosis (20%), and breast pain (9%) were observed. The resected breast tissue volumes of the patients who had Grade ≥ 2 fibrosis and Grade < 2 fibrosis were 105.9 ± 32.3 cm <superscript>3</superscript> and 76.3 ± 45.6 cm <superscript>3</superscript> , respectively, p = 0.02. The overall cosmetic outcome score of Excellent/Good was 74% at 60 months after APBI. Grade ≥ 1 fibrosis was observed in 44% and 92% of patients who scored Excellent/Good and Fair/Poor, respectively, p = 0.004.<br />Conclusions: This study showed excellent local control and survival results with minimal late sequelae.<br /> (© 2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society.)
Details
- Language :
- English
- ISSN :
- 1880-4233
- Volume :
- 29
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Breast cancer (Tokyo, Japan)
- Publication Type :
- Academic Journal
- Accession number :
- 35303282
- Full Text :
- https://doi.org/10.1007/s12282-022-01339-z